Impact of systemic inflammatory markers in patients with ALK-positive non-small cell lung cancer treated with crizotinib O.F. Olmez; A. Bilici; P. Gursoy; E. Cubukcu; A. Sakin; T. Korkmaz; I. Cil; B. Cakar; S. Menekse; T. Demir; O. Acikgoz; J. Hamdard;

T790M-EGFR mutation frequency in advanced NSCLC patients on progression from a previous TKI therapy: results from a Portuguese study Encarnação Teixeira; António Araújo; Venceslau Hespanhol; Bárbara Parente; Fernando Barata;